Timelines used to identify symptoms recorded in the 5 years before SLE diagnosis taking into account data censoring. Timelines used to identify symptoms.

Slides:



Advertisements
Similar presentations
Journal Club Alcohol and Health: Current Evidence January-February 2005.
Advertisements

Nurse Co-ordinated Rapid Access Chest Pain Clinic
The Clinical Practice Research Datalink Methodological Challenges in using Routine Clinical Data Dr Alison Nightingale, University of Bath.
Copyright © 2004 American Medical Association. All rights reserved.
The NAS2 audit requested whether CBTp was ‘taken up’, and we examined this in two ways: service users with at least one session of CBTp, which is represented.
Figure 1 Monogenic forms of diabetes mellitus
Subjects gain SLE classification through Systemic Lupus International Collaborating Clinics (SLICC) criteria of low complement, immunological manifestations.
Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Daniel J. Lenihan et al. BTS 2016;1:
Physician Diagnosis and Prescription
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.
Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.
National Cancer Statistics in Korea, 2015
Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.
Immunohistochemistry staining of interferon (IFN)-λ in renal tissue.
(A) Phospho-H2AX levels are significantly increased in CD4+ T cells, CD8+ T cells and monocytes from SLE compared with those from healthy controls (p=2.16×10−4,
Lupus Foundation of America-Rapid Evaluation of Activity in Lupus (LFA-REAL) comprised seven anchored Visual Analogue Scales (0–100 mm each) and can describe.
Miyako Igarashi et al. JACEP 2018;4:
Change in individual tolerability assessment between baseline and study completion. Change in individual tolerability assessment between baseline and study.
Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.
Immunohistochemistry (IHC) staining of interferon (IFN)-λ in renal tissue The figure demonstrates a repeated renal biopsy obtained from a patient after.
Pheochromocytoma in a Patient With End-Stage Renal Disease
Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlations of EBV-specific T-cells and disease activity of SLE patients. Correlation.
The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major organ involvement from their SLE (renal.
Representative ultrasound images of patients with SLE
No difference in T-cell response between SLE patients and healthy controls upon superantigen stimulation. No difference in T-cell response between SLE.
What is the name of the disorder presented below
Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.
Longitudinal changes in serum G3BP concentrations and SLEDAI in 15 patients with SLE. Each plot represents one patient. Longitudinal changes in serum G3BP.
Performance characteristics for multivariate assay SLE panel.
Study schemas. Study schemas. Upper panel: single-ascending dose study. Subjects with mild, stable systemic lupus erythematosus (SLE) were randomised to.
Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation.
Correlation between mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)
Post-test probabilities of systemic lupus erythematosus (SLE) at different pretest probabilities for a positive and negative cell-bound complement activation.
Correlations between two measures of type I interferon activity and serum galectin-3-binding protein in the SLE-IFN-α (n=26) and HC-IFN-α (n=10) cohorts.
Celiac disease as a model for SLE
First-generation modular analysis of acutely ill systemic lupus erythematosus (SLE) (flare or infection) versus inactive SLE. The modules are numbered;
Attributed cause of end-stage renal disease (ESRD) among 251 patients with SLE in the Georgia Lupus Registry who progressed to ESRD (1979–2012), overall.
Change in urinary protein to creatinine ratio (uPCR) as a function of serum C4, C3, anti-C1q, EC4d, EC3d and ECR1. Change in urinary protein to creatinine.
Comparison of the effects of growing podocytes in plasma from patients with lupus nephritis (LN), rheumatoid arthritis or non-renal lupus. Comparison of.
The left side images are T2 fat-saturated axial images showing the relevant finding, and the right side images are coronal PD fat-saturated images with.
Hierarchical clustering of non-classical monocytes from patients and controls, with tracks indicating individuals, IFN score, SLEDAI score and prednisone.
Distribution of the RAMRIS component scores sorted by pain score.
Presence of inpatient diagnostic codes for attributed cause of end-stage renal disease (ESRD) among 46 patients with systemic lupus erythematosus (SLE)
SLE deconvolution patient clusters and representative immune cell types (A), and distribution of patients by SLE deconvolution cluster and treatment group—all.
Least squares (LS) mean (SE) changes from baseline in (A) Cutaneous Lupus Erythematosus Disease Area and Severity Index activity scores and (B) Tender.
The kynurenic pathway. The kynurenic pathway. The encircled metabolites were measured and symbols indicate method and biological sample, that is, LC-MS/MS.
A proposed algorithm for the handling of glucocorticoid (GC) therapy in patients with active or flaring SLE. Mild: presence of only BILAG C or ≤1 BILAG.
Antibody levels to Ro52, Ro60, p200 and La antigens in control and congenital heart block (CHB) cohort were measured as bound units (BU). Antibody levels.
Proportion of patients consulting their general practitioner for symptoms within each British Isles Lupus Activity Group (BILAG) domain in the 5 years.
Presence of autoreactive anti-HLA antibodies among SLE and RA subjects
Impact of skin damage on health-related quality of life.
Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.
For patients with type 2 diabetes and DN, follow-up time was divided into time spent in the following clinical states: DN, CVD, and ESRD in chronologic.
Number of microparticles (MPs) and distribution of MP surface markers in patients with SLE and HCs. Three aliquots of MPs were incubated with (1) anti-CD3,
Postulated impact of SLE on endothelial nitric oxide (NO) synthase activity and endothelial nitric oxide synthase (eNOS) uncoupling. Postulated impact.
Plots showing the difference in expression rate versus the difference in averaged transcript amount between patients with SLE with SLEDAI ≥10 and those.
Mean change from baseline over time in BILAG score,
Overall gene expression in monocyte subsets in patients and controls.
Fig. 4 The distribution of the target diagnoses in premutation carriers and controls for codes received before age 40. The distribution of the target diagnoses.
(A) Mean urine protein/creatinine ratio (UPCR) and SEM in participants from the combined Lupus Nephritis Assessment of Rituximab (LUNAR) and A Study to.
IFN-γ-producing T-cells in SLE patients and healthy controls upon EBV antigen stimulation. IFN-γ-producing T-cells in SLE patients and healthy controls.
Activated T-cells in SLE patients and healthy controls upon EBV antigen stimulation. Activated T-cells in SLE patients and healthy controls upon EBV antigen.
Mean serum concentration time profiles of anifrolumab following subcutaneous and intravenous administration of anifrolumab.a aData below the limits of.
Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number.
Median percentage change in complement components 3 and 4 over time by SLE deconvolution cluster—all randomised and treated patients.* *Data from five.
Measures of endothelial activation/dysfunction are associated with QRISK3. Measures of endothelial activation/dysfunction are associated with QRISK3. Increased.
Overall and recurrence-free survival.
Fig. 1. Schematic description of whole-exome or targeted next-generation sequencing analyses. Schematic description of whole-exome or targeted next-generation.
Presentation transcript:

Timelines used to identify symptoms recorded in the 5 years before SLE diagnosis taking into account data censoring. Timelines used to identify symptoms recorded in the 5 years before SLE diagnosis taking into account data censoring. Patient A. Joins the Clinical Practice Research Database (CPRD) in 1995 (their left censoring date (LCENS—the blue arrow) and is diagnosed with SLE in 2000 (the red arrow). We require at least 2 years between their LCENS date and their date of SLE diagnosis to include them as an incident case of SLE (the pink box). We code symptoms of SLE in the 5 years before SLE diagnosis (the green box) and we can use all of those 5 years since their LCENS date is in 1995. Patient B. Joins the CPRD in 2004 (their LCENS date) therefore, we cannot see their medical records before 2004 (the grey box). They have at least 2 years of data between their LCENS (2004) and date of SLE diagnosis (2012). We can only use the 4 years of data between their date of SLE diagnosis and LCENS date to look for symptoms of SLE. Patient C. Joins the CPRD in 1998 (their LCENS date). They have their diagnosis of SLE in 2012. For this patient, we have 14 years of research standard data (between their LCENS and date of diagnosis). Therefore, they are an incident case of SLE as they have at least 2 years of data before their SLE diagnosis. We can use symptoms recorded in the 5 years before diagnosis to investigate the onset of SLE. Although we have much more data, we decided not to use data more than 5 years before diagnosis because the data became very unstable due to low numbers. Patient D. Joins the CPRD in 2001 (LCENS date) and has their date of SLE diagnosis in 2002. They do not have 2 years of research standard data in their record between their LCENS date and date of SLE diagnosis and therefore would have been excluded from the study because we do not have sufficient data to ascertain whether the patient is an incident or prevalent case of SLE. Alison L Nightingale et al. Lupus Sci Med 2017;4:e000172 ©2017 by Lupus Foundation of America